LUND, Sweden, Feb. 15, 2007-Collaboration initiated in January 2007 with Genentech, Inc., to co-develop and commercialize the company’s product candidate BI-204. BioInvent received the first payment of SEK 105.5 million in January. In addition, BioInvent could receive further milestone payments of up to about SEK 1.2 billion as well as royalties on sales in North America.
